Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

188.68B

Market cap188.68B

Price-Earnings ratio

24.31

Price-Earnings ratio24.31

Dividend yield

2.80%

Dividend yield2.80%

Average volume

2.28M

Average volume2.28M

High today

$356.50

High today$356.50

Low today

$345.08

Low today$345.08

Open price

$348.68

Open price$348.68

Volume

3.45M

Volume3.45M

52 Week high

$391.29

52 Week high$391.29

52 Week low

$267.83

52 Week low$267.83

Stock Snapshot

With a market cap of 188.68B, Amgen(AMGN) trades at $347.89. The stock has a price-to-earnings ratio of 24.31 and currently yields dividends of 2.8%.

On 2026-06-06, Amgen(AMGN) stock moved within a range of $345.08 to $356.50. With shares now at $347.89, the stock is trading +0.8% above its intraday low and -2.4% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 3.45M, versus its average volume of 2.28M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $267.83.

AMGN News

Nasdaq 24h

Amgen: A Biotech Giant's Path to Recovery and Growth

Explore the exciting world of Amgen (NASDAQ: AMGN) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to ga...

TipRanks 1d

Amgen price target lowered to $389 from $425 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Amgen (AMGN) to $389 from $425 and keeps a Buy rating on the shares. The firm is adjusting its model as the com...

Nasdaq 2d

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its...

Analyst ratings

47%

of 36 ratings

Buy

41.7%

Hold

47.2%

Sell

11.1%

More AMGN News

Simply Wall St 3d

Assessing Amgen Valuation After Imdelltra Approval And Concerns Over Tavneos And Prolia

Amgen (AMGN) is in focus after a packed stretch of product and earnings news, including European approval for Imdelltra in small cell lung cancer and fresh conc...

Simply Wall St 4d

EU Approval Of IMDYLLTRA Puts Amgen’s Lung Cancer Ambitions In Focus

European Commission approves Amgen's IMDYLLTRA (tarlatamab) for adults with extensive-stage small cell lung cancer as a second-line treatment. Decision follows...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.